Cargando…
Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer
BACKGROUND: The KRAS gene is mutated in about 40 % of colorectal cancer (CRC) cases, which has been clinically validated as a predictive mutational marker of intrinsic resistance to anti-EGFR inhibitor (EGFRi) therapy. Since nearly 60 % of patients with a wild type KRAS fail to respond to EGFRi comb...
Autores principales: | Omolo, Bernard, Yang, Mingli, Lo, Fang Yin, Schell, Michael J., Austin, Sharon, Howard, Kellie, Madan, Anup, Yeatman, Timothy J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069826/ https://www.ncbi.nlm.nih.gov/pubmed/27756306 http://dx.doi.org/10.1186/s12920-016-0225-2 |
Ejemplares similares
-
Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material
por: Steeghs, Elisabeth M. P., et al.
Publicado: (2020) -
Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling
por: Foster, Joseph M, et al.
Publicado: (2015) -
A streamlined method for analysing genome-wide DNA methylation patterns from low amounts of FFPE DNA
por: Ludgate, Jackie L., et al.
Publicado: (2017) -
High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays
por: Wang, Yuker, et al.
Publicado: (2009) -
Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples
por: Zakrzewski, Falk, et al.
Publicado: (2019)